Alnylam Gains Analyst Momentum Amid $340M Volume Rank 327th as BMO Ups Target to $470

, 2025, , ranking 327th in market activity. The stock remains near its 52-week high amid ongoing analyst scrutiny of its pipeline advancements.

, . , positioning it favorably for a cardiovascular outcomes trial. Analysts emphasized the potential for reimbursement and a six-month dosing regimen, .

Multiple institutions reiterated confidence in Alnylam's . H.C. , . , . , .

To build an accurate back-test I need a few clarifications about the strategy’s implementation: 1. Stock universe • Should I rank “all” U.S.–listed common stocks (NYSE + NASDAQ + AMEX)? • Do we exclude ETFs, ADRs, preferred shares, penny stocks, etc.? 2. Ranking rule and execution price • Rank each trading day’s stocks by that day’s total share volume, correct? • Open the position at the same day’s close and exit at the next day’s close (i.e., 1-day holding period)? • Equal-weight the 500 names each day? 3. Practical assumptions • Any transaction cost, slippage or liquidity filters you want applied? • Is a short “cool-down” window (e.g., skip stocks with suspended trading) necessary? Once these are confirmed I can generate the data-retrieval plan and run the back-test.